04 September 2019
Visiongain has launched a new pharma report Antibiotic Resistance Market Report: By Disease (CUTI, CIAI, BSI, CDI, ABSSSI, HABP/VABP, CABP), by Pathology (Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, E. coli/K. Pneumoniae, Streptococcus Pneumoniae, Clostridium Difficile, Enterococcus Faecium, Haemophilus Influenzae), by Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Others) and by Region.
Global Antibiotic Resistance Market is anticipated to grow on account of growing incidences of infectious diseases and burden of antibiotic resistant infections. The global antibiotic resistance market is anticipated to grow at a lucrative CAGR of 5.4% and anticipated to reach USD 14.14 Billion by 2029.
Antibiotic resistance is spreading rapidly across the globe. New mechanisms of resistance are emerging and spreading worldwide, threatening capacity of companies to treat prevalent infectious diseases. An increasing list of infections such as tuberculosis, pneumonia, gonorrhea, blood poisoning, and nutritional illnesses is becoming more difficult and sometimes impossible to treat as antibiotics become less efficient.
Where antibiotics can be purchased without a prescription for human or animal use, the development and spread of resistance is exacerbated. Similarly, antibiotics are often over-prescribed by health employees without conventional treatment guidelines and are over-used by the public.
Without immediate action, we are moving towards a post-antibiotic age where prevalent infections and minor wounds can be killed again. Antibiotic resistance has the ability to impact individuals at any point of life, as well as the healthcare, veterinary and farming sectors, making it one of the most pressing public health issues in the world. More than 2 million individuals are infected with antibiotic-resistant bacteria every year in the United States, resulting in the death of at least 24,000 individuals.
North America holds majority of market share followed by Europe and the growth is attributed to new drug launches and high supplement cost. Europe holds a significant market share and is anticipated to grow at a lucrative growth rate. Also, as per The Lancet Infectious Diseases, there is a burden of antibiotic resistant infections across European countries. Annually more than 32000 people die from antibiotic resistant bacterial infections in the European region and the burden is comparable to that from TB, HIV and influenza combined.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.
For example, through public-private partnerships, a joint initiative of the World Health Organization and Drugs for Neglected Diseases Initiative, GARDP promotes R&D in the field of antibiotics. By 2023, the partnership seeks at developing and delivering up to four new medicines by improving current antibiotics and accelerating the introduction of fresh antibiotic drugs.
The comprehensive market report features companies such as Allergan, AmpliPhi Biosciences, Biolytx Pharmaceuticals, BioVersys GmbH, Macrolide Pharmaceuticals, Melinta Therapeutics, Merck, Pfizer, Phage Technologies S.A, SelectX Pharmaceuticals, Inc. and Wockhardt therapeutics among other prominent players.
Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth